| Bioactivity | CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research[1]. | ||||||
| Name | CKLF1-C27 | ||||||
| CAS | 891861-48-6 | ||||||
| Shortening | ALIYRKLLFNPSGPYQKKPVHEKKEVL | ||||||
| Formula | C151H243N39O37 | ||||||
| Molar Mass | 3196.78 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
CKLF1-C27
CAS: 891861-48-6 F: C151H243N39O37 W: 3196.78
CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.